Even after a flurry of corporate updates during the first two days of the J.P. Morgan Healthcare Conference, many more ...

While obesity product sales will be driving the boon in 2025, industry experts are also eyeing promising new launches in ...

New immunology products Skyrizi (risankizumab ... AbbVie’s head of commercial Jeff Stewart said on the results call that the two products have “substantial room for continued growth ...

If you live in the United States, you’ve likely seen drug commercials like this one: “If you’re living with moderate to severe plaque psoriasis or active psoriatic arthritis, symptoms can sometimes ...

Trump’s pick to lead the Health Department is targeting a multibillion-dollar ad market that’s one of the biggest spenders on ...

Marla has worked in the healthcare industry since 2000, starting as a bench chemist with Pfizer in manufacturing. In 2006, ...

The draw of both Otezla and tapinarof is that they are avoid the regular injections needed for biologic psoriasis therapies like Novartis' Cosentyx (secukinumab) and AbbVie's Skyrizi (risankizumab ...

The US Food and Drug Administration (FDA) has approved Omvoh (mirikizumab-mrkz), from US pharma major Eli Lilly, for the ...

Skyrizi had an estimated national TV ad spend of $367.7 million — the highest ad spend of any brand in the top 10.

AbbVie closed out the year on a high note, as its blockbuster biologic Skyrizi once again claimed the top spot in 2024’s ...

AbbVie executives say the company’s immunology drugs Skyrizi and Rinvoq are expanding their reach in the inflammatory bowel disease (IBD) as the market for Humira biosimilars heats up.